Loading
A phase 2/3 trial testing HS-20117 in non-small-cell lung cancer, now recruiting.
A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer is a phase 2/3 interventional study registered as NCT06417008, led by Hansoh BioMedical R&D, and recruiting on the registry. Official title: A Phase Ib/III Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Immunogenicity of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer. Planned enrolment is 1080 participants (estimated). The study started in 2024-05-28 and primary completion is expected in 2026-06-01. No results have been posted on ClinicalTrials.gov.